Get the Stockscreener App
253.44
3.74%
9.14
After Hours:
258.00
4.56
+1.80%
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Free genetic testing for AHP offered by Alnylam Act in US, Canada - Porphyria News
Alnylam at Stifel’s 2025 CNS Forum: Advances in RNAi for Neurological Diseases - Investing.com
Alnylam Pharmaceuticals To Present At Stifel 2025 Virtual CNS Forum; Webcast At 3:00 PM ET - Nasdaq
Arbor raises $74M amid genetic medicine’s funding slump - BioPharma Dive
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
How Do Investors Really Feel About Alnylam Pharmaceuticals? - Benzinga
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum? - Nasdaq
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Victory Capital Management Inc. - Defense World
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - BioSpace
Antisense Oligonucleotides Market reached US$ 2,985.97 - openPR
Alnylam Pharmaceuticals’ SWOT analysis: strong data bolsters $8B amvuttra potential - Investing.com
Transthyretin Amyloidosis Treatment Market Is Booming - openPR
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00 at JPMorgan Chase & Co. - Defense World
Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews - Benzinga
Alnylam Reveals Latest CNS Therapeutics Strategy at Upcoming Stifel Forum - StockTitan
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire
Alnylam gearing up for Phase 3 trial of nucresiran in FAP late this year - FAP News Today
U.S. Transthyretin Amyloidosis Market Projected To Witness Substantial Growth, 2025-2032:Alnylam - EIN News
What is Zacks Research’s Estimate for ALNY Q1 Earnings? - Defense World
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Mutual of America Capital Management LLC - Defense World
FY2027 Earnings Forecast for ALNY Issued By Zacks Research - Defense World
Oppenheimer & Co. Inc. Has $404,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
(ALNY) Proactive Strategies - Stock Traders Daily
Alnylam Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by IFP Advisors Inc - Defense World
Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Alnylam Pharmaceuticals CSO Kevin Fitzgerald sells shares worth $669,303 By Investing.com - Investing.com Australia
Dr. Phillip A. Sharp Retirement From Alnylam Pharmaceuticals (NasdaqGS:ALNY) Board Announced - Simply Wall St
Principal Financial Group Inc. Reduces Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Announces Retirement of Board Member, Dr. Phillip A. Sharp - citybiz
Alnylam Pharmaceuticals Announces Retirement of Co-Founder Dr. Phillip A. Sharp - GuruFocus.com
Alnylam co-founder Dr. Sharp to retire from board in May - Investing.com India
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary - Business Wire
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals CEO Yvonne Greenstreet sells $700,893 in stock - Investing.com India
Alnylam Pharmaceuticals CFO sells $192,389 in stock - Investing.com
Alnylam Pharmaceuticals CFO sells $192,389 in stock By Investing.com - Investing.com UK
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
H.C. Wainwright maintains $500 target on Alnylam stock - Investing.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Truist Financial Corp - Defense World
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Allianz Asset Management GmbH - MarketBeat
Proficio Capital Partners LLC Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
National Pension Service Sells 36,876 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Y Intercept Hong Kong Ltd Purchases Shares of 4,516 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Chardan Capital - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from Needham & Company LLC - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $6.85 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Los Angeles Capital Management LLC Decreases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Illinois Municipal Retirement Fund Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Buy Rating from Chardan Capital - Defense World
RNAi Therapeutics and Technology Market Top Companies Study - openPR
William Blair Reaffirms Outperform Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - Defense World
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - MSN
William Blair Reiterates "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Biopharmaceutical index drops in 2024, but starts new year on a rebound - BioWorld Online
Alnylam Pharmaceuticals: Balancing Promising Pipeline with Competitive Challenges and Strategic Uncertainties - TipRanks
Investor Network: Alnylam Pharmaceuticals, Inc to Host Earnings Call - ACCESS Newswire
Equities Analysts Issue Forecasts for ALNY Q1 Earnings - MarketBeat
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):